The 351(k) Report
A consistent weekly read that helps teams stay oriented in the U.S. biosimilars market — what changed, what matters, and what to watch next.
Built for speed, clarity, and repeat use.
The 351(k) Report is designed to be used — not skimmed once and forgotten. Each issue follows a consistent structure so teams can quickly scan what changed, align internally, and decide what deserves deeper follow-up.
What’s inside
Weekly market moves
Launches, competitive shifts, and key developments—summarized in a repeatable format.
Pricing & reimbursement signals
What the market is signaling, where pressure is building, and what it may mean for access.
Grounded in consistent tracking
Built on steady monitoring of the market so trends emerge over time—not just in hindsight.
How access works
Subscribers receive the 351(k) Report on a consistent cadence and can access prior issues once logged in. If you’re exploring access for a team, contact us and we’ll help you pick the right path.
Want to see if it fits your team?
Start with the reports page, or reach out with a short note on what you’re trying to solve.